Anti-inflammatory and immunomodulatory effects of statins.

Anti-inflammatory and immunomodulatory effects of statins. 3-Hydroxy-3-methyl-gutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins constitute the most powerful class of lipid-lowering drugs. Clinical trials have demonstrated a marked reduction in cardiovascular mortality in patients treated with statins. However, the benefits observed with statin therapy appear to be related, at least in part, with their cholesterol-lowering independent effects. Extensive research carried out mainly in the last decade suggests that the clinical benefits of these drugs could be related to an improvement in endothelial dysfunction, a reduction in blood thrombogenicity, anti-inflammatory properties, and, recently, immunomodulatory actions. In this sense, statins decrease T cell activation, the recruitment of monocytes and T cells into the arterial wall, and enhance the stability of atherosclerotic lesions. Many of these effects are related with the inhibition of isoprenoid synthesis, which serve as a lipid attachment for a variety of proteins implicated in intracellular signaling. In fact, small G proteins, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in the lipid-lowering independent effects of HMG-CoA reductase inhibitors. This article summarizes the anti-inflammatory and immunomodulatory effects of statins and their participation in the different steps of atherosclerotic lesion formation.

[1]  J. Egido,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. , 2002, European journal of pharmacology.

[2]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[3]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[4]  W. Min,et al.  Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  E. Ros,et al.  Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. , 2002, Atherosclerosis.

[6]  S. Tonstad,et al.  Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. , 2002, Atherosclerosis.

[7]  Á. Pascual,et al.  3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. , 2002, Atherosclerosis.

[8]  P. Libby,et al.  CD40 Signaling and Plaque Instability , 2001, Circulation research.

[9]  K. Takeda,et al.  Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Fichtlscherer,et al.  Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. , 2001, Journal of the American College of Cardiology.

[11]  W. Daniel,et al.  Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets , 2001, Heart.

[12]  W. Daniel,et al.  Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.

[13]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[14]  D. Wheeler,et al.  Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. , 2001, Kidney international.

[15]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[16]  H. Arnesen,et al.  Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. , 2001, Atherosclerosis.

[17]  B. Kasiske,et al.  THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2 , 2001, Transplantation.

[18]  T. Lehtimäki,et al.  Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. , 2001, The American journal of cardiology.

[19]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[20]  A. Kumar,et al.  Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection , 2001, Clinical transplantation.

[21]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[22]  A. M. Lefer,et al.  Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[23]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[24]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[25]  J. Tijssen,et al.  Recurrent unstable angina after directional coronary atherectomy is related to the extent of initial coronary plaque inflammation. , 2001, Journal of the American College of Cardiology.

[26]  I. Holme,et al.  Effects of Fluvastatin on Cardiac Events in Renal Transplant Patients: ALERT (Assessment of Lescol® in Renal Transplantation) Study Design and Baseline Data , 2001, Journal of cardiovascular risk.

[27]  R. Frye,et al.  Molecular Fingerprint of Interferon-&ggr; Signaling in Unstable Angina , 2001, Circulation.

[28]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[29]  M Shiomi,et al.  Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic Rabbits , 2001, Circulation.

[30]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[31]  A. Szczeklik,et al.  Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. , 2001, International journal of cardiology.

[32]  C. Iadecola,et al.  Cerebral ischemia and inflammation , 2001, Current opinion in neurology.

[33]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[34]  W. Palinski.  Immunomodulation: a new role for statins? , 2000, Nature Medicine.

[35]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[36]  J. Egido,et al.  Red Wine Intake Prevents Nuclear Factor-&kgr;B Activation in Peripheral Blood Mononuclear Cells of Healthy Volunteers During Postprandial Lipemia , 2000, Circulation.

[37]  S. Basili,et al.  Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[38]  P. Ridker,et al.  Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. , 2000, Journal of the American College of Cardiology.

[39]  Y. Chao,et al.  Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  T. Awata,et al.  Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. , 2000, Life sciences.

[41]  K. Hirata,et al.  Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. , 2000, Biochemical and biophysical research communications.

[42]  P. Libby,et al.  HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[43]  A. M. Lefer,et al.  Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[44]  J. Egido,et al.  Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. , 1999, Atherosclerosis.

[45]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[46]  P. Libby,et al.  Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.

[47]  P. Libby,et al.  Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. , 1999, Circulation.

[48]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[49]  U. Laufs,et al.  3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1 * , 1999, The Journal of Biological Chemistry.

[50]  K. Kugiyama,et al.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. , 1999, Journal of the American College of Cardiology.

[51]  L. Simon.  Role and regulation of cyclooxygenase-2 during inflammation. , 1999, The American journal of medicine.

[52]  P. Libby,et al.  Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.

[53]  A. Allegra,et al.  Pro-apoptotic effect of fluvastatin on human smooth muscle cells. , 1999, European journal of pharmacology.

[54]  P. Meraj,et al.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.

[55]  D. Webb,et al.  Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. , 1999, Circulation.

[56]  S. Kaul,et al.  Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.

[57]  A. Dart,et al.  Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. , 1999, Journal of the American College of Cardiology.

[58]  A. Rebuzzi,et al.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.

[59]  M. Shiomi,et al.  Effect of cerivastatin sodium, a new inhibitor of HMG‐CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits , 1999, British journal of pharmacology.

[60]  J. Egido,et al.  HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.

[61]  J. Egido,et al.  ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. , 1998, The American journal of pathology.

[62]  F. Bernini,et al.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[63]  A. Maseri,et al.  Immune system activation follows inflammation in unstable angina: pathogenetic implications. , 1998, Journal of the American College of Cardiology.

[64]  M. E. Ritchie.  Nuclear Factor-κB Is Selectively and Markedly Activated in Humans With Unstable Angina Pectoris , 1998 .

[65]  Channing J Der,et al.  Rho family proteins and Ras transformation: the RHOad less traveled gets congested , 1998, Oncogene.

[66]  A. Ortiz,et al.  3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. , 1998, Circulation research.

[67]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[68]  E. Nishi,et al.  Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells , 1998, FEBS letters.

[69]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[70]  P. Libby,et al.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.

[71]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[72]  C. Sirtori,et al.  Direct effects of statins on the vascular wall. , 1998, Journal of cardiovascular pharmacology.

[73]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[74]  P. Libby,et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.

[75]  P. Ridker,et al.  Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men , 1998, The Lancet.

[76]  J. Flory,et al.  Effects of lovastatin on the immune system. , 1997, The American journal of cardiology.

[77]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[78]  A. Castaigne,et al.  Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. , 1997, Journal of the American College of Cardiology.

[79]  F. Vrtovsnik,et al.  Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. , 1997, Kidney international.

[80]  L. Van Aelst,et al.  Rho GTPases and signaling networks. , 1997, Genes & development.

[81]  G. Steinbeck,et al.  Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. , 1997, Circulation.

[82]  Murray Wm.  Inflammation, aspirin, and the risk of cardiovascular disease. , 1997 .

[83]  D. Granger,et al.  Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[84]  P. Libby,et al.  The Nuclear Factor κ-B Signaling Pathway Participates in Dysregulation of Vascular Smooth Muscle Cells in Vitroand in Human Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[85]  P. Barnes,et al.  Nuclear Factor-kappa B , 1997 .

[86]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[87]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[88]  A. Gori,et al.  Acute T-cell activation is detectable in unstable angina. , 1997, Circulation.

[89]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[90]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[91]  P. Baeuerle,et al.  Role of nuclear factor‐kappa B in atherogenesis , 1997, Experimental physiology.

[92]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[93]  P. Ganz,et al.  Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. , 1997, Circulation.

[94]  T. Totsuka,et al.  Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. , 1996, International journal of immunopharmacology.

[95]  M J Davies,et al.  Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. , 1996, Circulation.

[96]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[97]  J. Hokanson,et al.  Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. , 1996, Circulation.

[98]  Y. Shimada,et al.  Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. , 1996, Immunopharmacology.

[99]  S. Katznelson,et al.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. , 1996, Transplantation.

[100]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[101]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[102]  R. Knuechel,et al.  Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.

[103]  C. Ballantyne,et al.  Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .

[104]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[105]  J. Witztum,et al.  T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[106]  E. Arbustini,et al.  Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. , 1995, The American journal of cardiology.

[107]  A. Quyyumi,et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.

[108]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[109]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[110]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[111]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[112]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[113]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[114]  B. Mach,et al.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. , 1994, Science.

[115]  V. Fuster,et al.  Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.

[116]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[117]  Y. Ben-Neriah,et al.  Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB , 1993, Nature.

[118]  G. Gabbiani,et al.  Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. , 1993, Atherosclerosis.

[119]  A. Lusis,et al.  Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. , 1993, The Journal of clinical investigation.

[120]  E. Donetti,et al.  HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[121]  P. Baeuerle,et al.  The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. , 1993, The Biochemical journal.

[122]  B. Giusti,et al.  Transient Intermittent Lymphocyte Activation Is Responsible for the Instabilit of Angina , 1992, Circulation.

[123]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[124]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[125]  P. Lipsky,et al.  Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. , 1981, Journal of immunology.

[126]  M. Acemoglu,et al.  HMG-CoA reductase inhibitors , 2005 .

[127]  V. Campese,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[128]  J. Egido,et al.  Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. , 2003, Cardiovascular research.

[129]  W. Edwards,et al.  Nuclear factor-κB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris , 2002 .

[130]  J. Egido,et al.  Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. , 2002, Atherosclerosis.

[131]  P. Serruys,et al.  A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.

[132]  E. Lakatta,et al.  Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. , 1996, The American journal of pathology.

[133]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[134]  M. Bond,et al.  Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries. , 1990, The American journal of pathology.

[135]  A. Bankhurst,et al.  Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. , 1989, International journal of immunopharmacology.

[136]  M Lappé,et al.  Genetic control. , 1972, The New England journal of medicine.